We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Alexion's Soliris Blood Drug Draws New Patent Cases

Law360 (March 19, 2007, 12:00 AM EDT) -- Just days after Alexion Pharmaceuticals Inc.’s blood antibody drug Soliris was approved by the United States Food and Drug Administration, two parties have filed a lawsuit claiming the drug infringes on their patents.

Alexion’s Soliris drug is the first humanized antibody approved by the FDA to treat a rare blood disorder, paroxysmal nocturnal humoglobinuria (PNH), which strikes one in a million people and can lead to disability and a premature death.

The drug does not cure PNH, but rather stops the body from breaking down abnormally...
To view the full article, register now.